BrighTNess trial: no benefit from the addition of veliparib to neoadjuvant chemotherapy in TNBC
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi
HER2+ breast cancer: from no hope to good prognosis in 20 years
Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials
Potential advance in HER+ patients with combination therapy
Results from the monarcHER and KATE2 trials presented